
## Mamta Gupta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10070823/publications.pdf Version: 2024-02-01



MAMTA CHIDTA

#	Article	IF	CITATIONS
1	Spectrum of MRI Features of Mucin-producing Neoplasms in the Abdomen and Pelvis. Radiographics, 2022, 42, 469-486.	3.3	4
2	Urothelial Carcinoma of the Bladder With a Rare Solitary Metastasis to the Ovary. Urology, 2020, 135, 24-27.	1.0	4
3	Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential ( <scp>STUMP</scp> ): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters. Histopathology, 2018, 73, 284-298.	2.9	45
4	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression Journal of Clinical Oncology, 2017, 35, 4573-4573.	1.6	1
5	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget, 2017, 8, 103428-103436.	1.8	19
6	TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?. Human Pathology, 2016, 54, 82-91.	2.0	45
7	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival Journal of Clinical Oncology, 2016, 34, e23221-e23221.	1.6	1
8	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1158-1164.	3.4	237
9	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases Journal of Clinical Oncology, 2014, 32, 4585-4585.	1.6	5
10	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases Journal of Clinical Oncology, 2014, 32, 467-467.	1.6	13
11	Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood, 2012, 119, 476-487.	1.4	91